Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Immuneering Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- COMPANY NOW PLANS TO SHARE UPDATED OS AND PFS DATA FROM FIRST-LINE PANCREATIC CANCER PATIENTS (N = 34) TREATED WITH ATEBIMETINIB + MGNP IN Q3 2025, EARLIER THAN PRIOR GUIDANCE- - EXCEPTIONAL 94% OVERALL SURVIVAL (OS) OBSERVED AT 6 MONTHS IN ONGOING PHASE 2A TRIAL OF ATEBIMETINIB PLUS MODIFIED GEMCITABINE/NAB-PACLITAXEL (MGNP) IN FIRST-LINE PANCREATIC CANCER PATIENTS (N = 34)- - NEWLY ISSUED U.S. COMPOSITION OF MATTER PATENT FOR ATEBIMETINIB EXPECTED TO PROVIDE EXCLUSIVITY INTO 2042, WITH SUBSEQUENT OPPORTUNITY FOR PATENT TERM EXTENSION - - REQUEST FOR END OF PHASE 2 MEETING HAS BEEN SUBMITTED TO THE FDA; PIVOTAL TRIAL EXPECTED TO INITIATE IN 2026 - CAMBRIDGE, MASS., AUG. 13, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY OUTPACING CANCER TO HELP PATIENTS OUTLIVE THEIR DISEASE, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED SEVERAL BUSINESS UPDATES.

IMMUNEERING REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

- NEWLY ISSUED U.S. COMPOSITION OF MATTER PATENT EXPECTED TO PROVIDE EXCLUSIVITY INTO 2042, WITH SUBSEQUENT OPPORTUNITY FOR PATENT TERM EXTENSION - - FIRST U.S. PATENT GRANTED ON A DEEP CYCLIC INHIBITOR: A ONCE-DAILY PILL THAT AIMS TO DRIVE LONGER-LASTING BENEFIT BY OUTPACING RESISTANCE MECHANISMS THAT CAUSE CANCER DRUGS TO STOP WORKING - - ADDITIONAL PATENT APPLICATIONS PENDING FOR ATEBIMETINIB DIRECTED TO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE WITH EXPIRATION EXPECTED INTO 2044 - CAMBRIDGE, MASS., JULY 09, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY OUTPACING CANCER TO HELP PATIENTS OUTLIVE THEIR DISEASE, TODAY ANNOUNCED THAT THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) GRANTED THE COMPANY A COMPOSITION OF MATTER PATENT FOR ATEBIMETINIB (IMM-1-104), AN ORAL ONCE-DAILY DEEP CYCLIC INHIBITOR OF MEK.

IMMUNEERING GRANTED U.S. COMPOSITION OF MATTER PATENT FOR HIGHLY DIFFERENTIATED CANCER DRUG CANDIDATE ATEBIMETINIB

- 94% OS AND 72% PFS OBSERVED AT 6 MONTHS FOR ATEBIMETINIB (IMM-1-104) IN COMBINATION WITH MODIFIED GEMCITABINE/NAB-PACLITAXEL (MGNP), N=34; MEDIAN OS AND PFS NOT YET REACHED - - STRIKING TUMOR REDUCTIONS WITH 39% OVERALL RESPONSE RATE AND 81% DISEASE CONTROL RATE OBSERVED AS OF THE DATA CUTOFF, INCLUDING MANY PATIENTS WITH DEEPENING, DURABLE REGRESSIONS AND MULTIPLE EXAMPLES OF INDIVIDUAL LESIONS RENDERED UNDETECTABLE - - MARKEDLY FAVORABLE TOLERABILITY PROFILE OBSERVED, DEMONSTRATING POTENTIAL BEST-IN-CLASS PROFILE - - PIVOTAL TRIAL OF ATEBIMETINIB IN COMBINATION WITH MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS PLANNED FOR 2026 - - COMPANY TO HOST CONFERENCE CALL AT 8:00 A.M. ET TODAY - CAMBRIDGE, MASS.

IMMUNEERING REPORTS POSITIVE OVERALL SURVIVAL DATA FOR ATEBIMETINIB (IMM-1-104) FROM ONGOING PHASE 2A TRIAL IN FIRST-LINE PANCREATIC CANCER PATIENTS

CAMBRIDGE, MASS., JUNE 16, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY OUTPACING CANCER TO HELP PATIENTS OUTLIVE THEIR DISEASE, TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST AT 8:00 AM ET ON JUNE 17, 2025.

IMMUNEERING TO PROVIDE UPDATES FROM PHASE 2A CLINICAL TRIAL OF IMM-1-104 IN FIRST-LINE PANCREATIC CANCER PATIENTS ON TUESDAY, JUNE 17, 2025

CAMBRIDGE, MASS., MAY 29, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY SEEKING TO DEVELOP AND COMMERCIALIZE MORE EFFECTIVE AND BETTER TOLERATED THERAPIES FOR CANCER PATIENTS, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE, WHICH IS TAKING PLACE AT THE MARRIOTT MARQUIS IN NEW YORK CITY FROM JUNE 4-5, 2025, TO DISCUSS THE COMPANY'S PIPELINE, PLATFORM, AND BUSINESS STRATEGY.

IMMUNEERING TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

- PROGRESSION-FREE SURVIVAL DATA FROM MORE THAN 30 PATIENTS WITH FIRST LINE PANCREATIC CANCER IN THE ONGOING PHASE 2A TRIAL OF IMM-1-104 TRIAL PLANNED FOR ANNOUNCEMENT IN 2Q'25 - - REPORTED POSITIVE DATA FROM THE COMPANY'S ONGOING PHASE 2A TRIAL OF LEAD PROGRAM IMM-1-104, INCLUDING ENCOURAGING RESPONSES IN COMBINATION WITH CHEMOTHERAPY IN FIRST-LINE PANCREATIC CANCER, AND AS MONOTHERAPY IN SECOND-LINE PANCREATIC CANCER - - ANNOUNCED CLINICAL TRIAL SUPPLY AGREEMENT WITH REGENERON PHARMACEUTICALS TO EVALUATE IMM-1-104 IN COMBINATION WITH LIBTAYO (CEMIPLIMAB) IN NON-SMALL CELL LUNG CANCER - - NAMED INDUSTRY VETERAN DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER, TO LEAD CLINICAL EFFORTS AS THE COMPANY RAMPS UP PLANNING FOR PHASE 3 TRIAL IN FIRST LINE PANCREATIC CANCER - - CASH RUNWAY EXTENDED INTO 2026 - CAMBRIDGE, MASS., MAY 05, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY SEEKING TO DEVELOP AND COMMERCIALIZE MORE EFFECTIVE AND BETTER TOLERATED THERAPIES FOR CANCER PATIENTS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED SEVERAL BUSINESS UPDATES.

IMMUNEERING REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

CAMBRIDGE, MASS., APRIL 02, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY SEEKING TO DEVELOP AND COMMERCIALIZE MORE EFFECTIVE AND BETTER TOLERATED THERAPIES FOR CANCER PATIENTS, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE, WHICH IS TAKING PLACE FROM APRIL 7-10, 2025, TO DISCUSS THE COMPANY'S PIPELINE, PLATFORM, AND BUSINESS STRATEGY.

IMMUNEERING TO PRESENT AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

CAMBRIDGE, MASS., MARCH 21, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY SEEKING TO DEVELOP AND COMMERCIALIZE MORE EFFECTIVE AND BETTER TOLERATED THERAPIES FOR CANCER PATIENTS, PREVIOUSLY ANNOUNCED ON MARCH 20, 2025, THAT IGOR MATUSHANSKY, M.D.

IMMUNEERING CORPORATION ANNOUNCES GRANT OF INDUCEMENT AWARD

- REPORTED POSITIVE DATA UPDATES FROM ITS ONGOING PHASE 2A TRIAL OF LEAD PROGRAM IMM-1-104, INCLUDING ENCOURAGING RESPONSES IN COMBINATION WITH CHEMOTHERAPY IN FIRST-LINE PANCREATIC CANCER - - ANNOUNCED A CLINICAL TRIAL SUPPLY AGREEMENT WITH REGENERON PHARMACEUTICALS TO EVALUATE IMM-1-104 IN COMBINATION WITH LIBTAYO (CEMIPLIMAB) IN NON-SMALL CELL LUNG CANCER - - ADDITIONAL IMM-1-104 PHASE 2A DATA UPDATES AND INITIATION OF NEW IMM-1-104 COMBINATION ARMS EXPECTED IN 2025; PLANNING UNDERWAY FOR POTENTIAL IMM-1-104 GLOBAL PIVOTAL TRIAL - - NAMED INDUSTRY VETERAN DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER - - CASH RUNWAY EXTENDED INTO 2026 - CAMBRIDGE, MASS., MARCH 20, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY SEEKING TO DEVELOP AND COMMERCIALIZE MORE EFFECTIVE AND BETTER TOLERATED THERAPIES FOR CANCER PATIENTS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024, AND PROVIDED RECENT BUSINESS UPDATES.

IMMUNEERING REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

INDUSTRY VETERAN BRINGS EXTENSIVE ONCOLOGY DRUG DEVELOPMENT EXPERTISE AND EXPERIENCE IN CLINICAL TREATMENT OF CANCER PATIENTS DR. MATUSHANSKY JOINS AS IMMUNEERING PLANS TO PRESENT UPDATED DATA FROM PHASE 2A TRIAL OF IMM-1-104 IN PANCREATIC CANCER IN Q2 2025 CAMBRIDGE, MASS., MARCH 20, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY SEEKING TO DEVELOP AND COMMERCIALIZE MORE EFFECTIVE AND BETTER TOLERATED THERAPIES FOR CANCER PATIENTS, TODAY ANNOUNCED THAT IGOR MATUSHANSKY, MD, PHD, HAS JOINED THE COMPANY AS CHIEF MEDICAL OFFICER.

IMMUNEERING NAMES DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER

CAMBRIDGE, MASS., FEB. 03, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE ONCOLOGY COMPANY SEEKING TO DEVELOP AND COMMERCIALIZE MORE EFFECTIVE AND BETTER TOLERATED THERAPIES FOR CANCER PATIENTS, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE, WHICH IS TAKING PLACE VIRTUALLY FROM FEBRUARY 11-12, 2025, TO DISCUSS THE COMPANY'S PIPELINE, PLATFORM, AND BUSINESS STRATEGY.

Immuneering Corporation

IMRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immuneering Corporation

IMRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMRX